
TWINCREST, LLC has formed a joint venture with Pathology Solutions, LLC, to offer expanded in-office pathology services for specialty medical practices.

TWINCREST, LLC has formed a joint venture with Pathology Solutions, LLC, to offer expanded in-office pathology services for specialty medical practices.

Mitchell H. Sokoloff, MD, has been appointed chief of the section of urology and professor of surgery at the University of Arizona department of surgery. In this capacity, his objective will be to expand clinical, educational, and research programs in laparoscopy, voiding dysfunction, and urologic cancers, and to build a pediatric urology program in collaboration with university and community physicians.

Dendreon Corp. has initiated its second of two new phase II trials of sipuleucel-T (Provenge), the company’s investigational active cellular immunotherapy for the treatment of advanced prostate cancer.

Although cigarette smoking accounts for up to half of all bladder cancer cases, few people are aware of the connection, including more than three-quarters of patients who have the disease, according to a new study from the University of Michigan Comprehensive Cancer Center, Ann Arbor. This knowledge vacuum suggests that urologists need to communicate the risks of smoking to their patients and encourage them to quit, study authors say.

Brachytherapy may be a more beneficial treatment than surgery or external beam radiation therapy for overweight or obese prostate cancer patients, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2008; 71:1302-8).

One-fifth of men under age 50 reported undergoing a PSA test to detect prostate cancer in the previous year, yet only one in three young African-American men reported ever having had a PSA test in the previous year, according to researchers at the Duke University Prostate Center (Durham, NC). The findings appear in the June 23 online edition of Cancer and will appear in the Sept. 15 print edition.

A daily dose of tadalafil (Cialis) may relieve lower urinary tract symptoms in men with BPH symptoms, according to a study published in the Aug. 21 online edition of The Journal of Urology.


An investigational vitamin D agonist significantly slowed prostate growth and improved prostate symptoms and urinary flow in men with symptomatic benign prostatic hyperplasia.

In this interview, John Barry, MD, who began his term as AUA president in May, discusses these concerns, how AUA is addressing them, and the challenges and opportunities that lie ahead.

Patients with low-risk prostate cancer, whether ulilateral or bilateral, may be considered for focal ablative therapy.

Thepractice of physicians generating revenue from imaging services to which they refer their patients has come under federal scrutiny.


Focal cryotherapy, defined as less than complete ablation of the prostate gland with ice, potentially offers targeted local cancer control, preserving sexual potency and urinary continence in patients whose cancer is believed to be unilaterally clinically significant.

If you determine that the life insurance you bought years ago is no longer needed to provide for a surviving family, it can be canceled or given to your favorite charitable not-for-profit entity.

Here are steps and suggestions for getting your book idea to a publisher and seeing your work in print and on the bookshelves.

You can update a past medical, family, and social history (PFS) and ROS without having to rewrite it each time.

Approximately 5% of men who undergo vasectomy eventually will consider vasectomy reversal, and this demographic appears to be increasing.

Viable prostate cancer was detected on histologic examination of the surgical specimen from about half of patients who underwent radical cystoprostatectomy for nonprostate cancer-related disease after having received definitive radiation therapy for localized prostate cancer.

Laparoscopic radical prostatectomy for clinically localized prostate cancer is associated with very good long-term oncologic control.

An investigational gonadotropin-releasing hormone blocker produces an almost immediate reduction in the testosterone levels of patients undergoing treatment for prostate cancer.

In a trial of alpha-blocker therapy for men with newly diagnosed chronic prostatitis/chronic pelvic pain syndrome, placebo and treatment groups had the same proportion of responders: 49 percent.

A disproportionate influence of fat mass accounts for the relationship between body mass index and lower urinary tract symptoms.

Medicolegal issues in urology, discusses the impact of medical errors on the health care system and lists several goals designed to ensure your patients' safety.

Studies suggest that diet can have a significant impact on the incidence, progression, and mortality of prostate cancer.

Successfully orienting and retaining a new physician in your practice.

Young men diagnosed with prostate cancer are more likely to have aggressive disease and better progression-free survival than older men.

There are no high-level data to support current screening practices for PSA in men of any age, particularly in older men with a shorter life expectancy.

A wide array of novel targeted prostate cancer therapies are in progress or planned for the very near future.

Men who receive some form of radiotherapy for localized prostate cancer have an elevated risk of later developing bladder and rectal cancers.